Cancer and the loss of growth control

Why normal cells do not keep multiplying

Cell growth is regulated at several levels. Signals influence entry into division, cell-cycle checkpoints help identify problems, DNA repair addresses some damage, and certain irreparably damaged cells die or cease dividing. These are interacting systems that preserve tissue organization. Wound healing temporarily requires more cells, but that expansion should subside after repair.

Cancer development often involves several regulatory failures that allow inappropriate survival, proliferation, and invasion. Rapid growth alone is not a definition of cancer: normal tissues may grow quickly, while some cancers progress slowly. Assessment depends on cellular characteristics, tissue architecture, invasion, and other evidence. A lump might also represent inflammation, a cyst, or a benign tumor. Assessing a lump’s size by touch cannot replace diagnosis. This distinction explains why the same visible finding can lead to quite different investigations and treatments, and why a familiar symptom cannot reliably identify a cancer type.

NCI: What Is Cancer?

Driver changes, selection, and variation

Overactive growth-promoting genes, loss of growth restraints, and impaired DNA repair can contribute to cancer. Not every detected genetic change drives the disease; some accompany the process without providing a growth advantage. Repeated division can create distinct cell populations within a tumor. Treatment and environmental pressures may suppress some populations while allowing others to survive, helping explain why an initially effective treatment can later lose effect.

Cells do not intentionally resist therapy. Variation and selection provide a biological explanation. They also show why one biopsy has limits: it samples a particular location at a particular time. Repeat sampling or molecular testing may address a new question created by disease evolution, rather than prove that an earlier test was wrong. Careful explanation distinguishes established mechanisms, hypotheses about an individual patient, and remaining uncertainty. That distinction matters when interpreting promises about a supposedly universal cancer cure.

NCI: What Is Cancer?

Genetic does not necessarily mean inherited

Cancer involves genetic changes, but most cancer-causing changes arise in somatic cells during life. A change found in a tumor is not automatically passed to children. Germline variants may be inherited or arise newly and can alter susceptibility to certain cancers. Greater susceptibility changes probability; it does not guarantee disease. Conversely, an unremarkable family history does not guarantee absence of risk.

Tumor testing often characterizes the cancer or identifies treatment possibilities. Inherited-risk testing can influence decisions for a person and relatives. Their purposes, samples, and interpretation differ. If a familiar gene name appears in a tumor report, the useful question is whether the finding is confined to the tumor or has been confirmed in the germline. It is premature to assume relatives share it. Genetic counseling can help address confirmation, privacy, family communication, and prevention options that actually follow from the result.

NCI: The Genetics of Cancer

Invasion, metastasis, stage, and grade

Invasion means extension into nearby tissue; metastasis means spread from the primary site to another location. Breast cancer found in the lung is generally metastatic breast cancer, not a new primary lung cancer merely because of its location. This distinction affects pathology interpretation and treatment. Some cancers, including certain blood malignancies, do not follow the pattern of a single solid mass.

Stage mainly describes disease extent, while grade describes microscopic features and related biological behavior. They are not interchangeable. TNM information is used for many solid cancers, but rules differ by cancer type and cannot be transferred mechanically between diseases. Stage helps organize treatment and compare groups; it is not an individual countdown. Molecular features, overall health, available treatment, and response also matter. A population survival estimate describes a group and cannot precisely predict how long one particular person will live.

NCI: Cancer Staging

Clarify the purpose of treatment

Surgery and radiotherapy often target disease in a particular location, while medicines may act throughout the body. The combination depends on the cancer and clinical situation. Targeted therapy requires relevant biological features and is not suitable for every patient. Immunotherapy is more specific than simply strengthening immunity in general. Treatment may aim to cure, reduce recurrence, delay progression, or relieve symptoms; these purposes imply different measures of benefit and acceptable burdens.

Tumor shrinkage is useful information, but it does not automatically establish longer survival or better quality of life. Those outcomes require evidence. Palliative care can accompany anticancer treatment and address pain, breathlessness, anxiety, and family needs. It is not limited to the period after treatment stops. Useful questions concern the intended outcome, relevance of study participants, monitoring of harms, and the decision process if the expected benefit does not occur.

NCI: Types of Cancer Treatment

NCI: Palliative Care in Cancer

Reasoning: the same organ does not mean the same plan

Two people have malignant disease in the lung. One has primary lung cancer; the other has metastases from another organ. Location alone does not justify the same drug. Pathology, primary site, stage, molecular findings, previous treatment, and physical functioning provide the basis for comparison. A social-media story about someone responding to a medicine is an individual observation, not a substitute for an indication or research evidence.

If relatives request the strongest treatment, clarify whether they mean a greater chance of shrinkage, longer survival, or simply more intense adverse effects. Intensity is not equivalent to efficacy. Shared decisions identify achievable goals, compare absolute benefits and burdens, and consider activities and relationships the patient values. Honest ranges and a planned reassessment are more useful than unsupported guarantees. Cancer education also has a role in resisting blame, stigma, and false promises of a cure.

Does a larger cell proportion mean a larger cell count?

Cells within a tumor can respond differently to the same treatment. Consider a deliberately simplified fictional model: group A is more affected by this treatment than group B. Assume we know the entire population of both groups, compare two time points, and introduce no new mutations. The numbers are not effects measured for any cancer or drug.

Group B remains at 100 cells. Its share nevertheless rises from 100 ÷ 1000 = 10% to 100 ÷ 190 ≈ 52.6%, because group A shrinks substantially. A larger share does not establish that B multiplied, and it does not mean cells deliberately learned to resist. The model shows how selection acting on existing differences can change population composition.

Real tumors contain more than two simple groups, and treatment-related change follows more than one pathway. A real sample usually comes from a particular place and time; it does not reveal every cell in every lesion as our model assumes. Different proportions in two samples also require attention to sampling location and representativeness. Absolute cell counts, proportions within a sample, and the overall clinical course are distinct kinds of information.

NCI: Tracking Treatment Resistance in Metastatic Breast Cancer

Bilingual terms

侵袭 · Invasion

Extension of malignant cells into neighboring tissue.

转移 · Metastasis

Cancer spread establishing disease away from its primary site.

体细胞变异 · Somatic variant

A genetic change in cells outside the germline.

分期 · Stage

Classification of disease extent.

分级 · Grade

Assessment of tumor characteristics from microscopic features.

Sources and further reading

• NCI: What Is Cancer?
• NCI: The Genetics of Cancer
• NCI: Cancer Staging
• NCI: Types of Cancer Treatment
• NCI: Palliative Care in Cancer
• NCI: Tracking Treatment Resistance in Metastatic Breast Cancer

Original course source-check record: 9 September 2026. Full Chinese and English sentence-by-sentence language review: 14 September 2026. AI editing and language review are not human clinical review. Linked institutions have not participated in or endorsed this course.